Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 2:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 901 matching trials from the live ClinicalTrials.gov search.
Conditions
Kidney Transplant, Hepatitis C, HCV
Interventions
Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET]
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Cardiovascular Diseases, Hepatitis C, Hiv
Interventions
Elbasvir / Grazoprevir Oral Tablet [Zepatier], Cardiac MRI
Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Conditions
Hepatitis C
Interventions
PF-00868554, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
9
States / cities
La Jolla, California • San Francisco, California • Orlando, Florida + 5 more
Conditions
Chronic Hepatitis C Virus
Interventions
LDV/SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
647 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
52
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 49 more
Conditions
Hepatitis C
Interventions
Ribavirin, Peg interferon alfa 2b, induction therapy
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Completed Not applicable Interventional Accepts healthy volunteers

Birth-Cohort Evaluation to Advance Screening and Testing for Hepatitis C

NCT02123212
Conditions
Hepatitis C, Chronic Hepatitis C
Interventions
Mailer, In-person recruitment, EHR Alert
Other
Lead sponsor
National Opinion Research Center
Other
Eligibility
47 Years to 69 Years
Enrollment
29,607 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
3
States / cities
Birmingham, Alabama • Detroit, Michigan • New York, New York
Conditions
HIV Infections, Hepatitis C
Interventions
Efavirenz, Lamivudine, Lopinavir/ritonavir, Pegylated interferon alfa-2a, Ribavirin, Tenofovir disoproxil fumarate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
2
States / cities
New York, New York • Dallas, Texas
Completed Not applicable Interventional Results available

Linkage to Care for Persons With Hep C Infection

NCT05397067
Conditions
Hepatitis C, Chronic, Substance Use Disorders
Interventions
Peer specialist (PS), Incentives, telehealth visits, phone access
Behavioral
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Roanoke, Virginia
Conditions
Ebola Virus Disease, Marburg Virus Disease
Interventions
cAd3-Marburg, cAd3-EBO-S
Biological
Lead sponsor
Albert B. Sabin Vaccine Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Conditions
HIV-1 and Hepatitis C Co-Infection
Interventions
pioglitazone, peginterferon, ribavirin
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
8
States / cities
San Francisco, California • Chicago, Illinois • Newark, New Jersey + 4 more
Conditions
Hepatitis C Virus Infection
Interventions
Simplified Hepatitis C Virus (HCV) Treatment Protocol
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Austin, Texas
Conditions
Hepatitis C Virus Infection, Infection, Herpesvirus 2, Human
Interventions
Valacyclovir
Drug
Lead sponsor
G.V. (Sonny) Montgomery VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Jackson, Mississippi
Conditions
Hepatitis C, Chronic
Interventions
Pegylated-interferon Alfa-2a, Ribavirin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Completed Phase 3 Interventional Accepts healthy volunteers

Chronic Hepatitis Intervention Project for Drug Users

NCT00596843
Conditions
HIV, Hepatitis C
Interventions
Motivational interviewing, Educational intervention
Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years and older
Enrollment
851 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Hepatitis C Virus Infection
Interventions
Sofosbuvir, Glecaprevir/Pibrentasvir, Ribavirin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years to 99 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
8
States / cities
Dothan, Alabama • Los Angeles, California • Baltimore, Maryland + 5 more
Conditions
Hepatitis C
Interventions
Eltrombopag, Lopinavir/Ritonavir, Eltrombopag and Lopinavir/Ritonavir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Hepatitis C, Chronic, Hepatitis C
Interventions
GSK625433/placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Evansville, Indiana
Conditions
HCV Infection
Interventions
placebo, GS-9190, Peginterferon Alfa 2a, Ribavirin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
48
States / cities
Anaheim, California • Los Angeles, California • Newport Beach, California + 37 more
Conditions
Chronic Hepatitis C Virus (HCV) Infection Genotype 1
Interventions
ABT-450/r/ABT-267, ABT-333, Ribavirin (RBV)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
615 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
48
States / cities
Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 40 more
Conditions
Hepatitis C, Pregnancy
Interventions
ledipasvir/sofosbuvir
Drug
Lead sponsor
Catherine Chappell
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Hepatitis C, Chronic
Interventions
Ribavirin, peginterferon alfa-2a [Pegasys]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
948 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
36
States / cities
Mobile, Alabama • Scottsdale, Arizona • Los Angeles, California + 30 more
Conditions
Hepatitis C, Chronic
Interventions
Peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
49
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 41 more
Conditions
Liver Transplant, Hepatitis C, Chronic Kidney Disease, Acute Rejection
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Hepatitis C, Chronic
Interventions
Copegus placebo, RO5024048, danoprevir, peginterferon alfa-2a [Pegasys], ribavirin [Copegus], ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
18
States / cities
La Jolla, California • Sacramento, California • Orlando, Florida + 14 more